The estimated Net Worth of Barbara Kosacz is at least $25.6 millió dollars as of 4 January 2024. Ms. Kosacz owns over 10,676 units of XOMA Royalty stock worth over $25,193,558 and over the last 6 years she sold XOMA stock worth over $12,598. In addition, she makes $350,390 as Independent Director at XOMA Royalty.
Barbara has made over 2 trades of the XOMA Royalty stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 10,676 units of XOMA stock worth $12,598 on 4 January 2024.
The largest trade she's ever made was selling 10,676 units of XOMA Royalty stock on 4 January 2024 worth over $12,598. On average, Barbara trades about 937 units every 69 days since 2019. As of 4 January 2024 she still owns at least 928,966 units of XOMA Royalty stock.
You can see the complete history of Ms. Kosacz stock trades at the bottom of the page.
Barbara A. Kosacz J.D. serves as Independent Director of the Company. Ms. Kosacz has been a director since January 2019. Ms. Kosacz has more than 25 years of experience in counseling clients in the life sciences arena, ranging from early stage startups to larger public companies, venture funds, investment banks, and non-profit institutions. She has served as a member of the BIO Emerging Companies’ Section Governing Board, is a member of the Board of Trustees of the Keck Graduate Institute, an advisory board member of Locust Walk Partners, and has been a speaker at multiple life sciences-related conferences, as well as guest lecturer at the University of California, Berkeley (Boalt Hall), and Stanford University about biotechnology law, biotech business models, corporate partnering negotiations and deal structures, and bioethics. Recognized by Best Lawyers in America since 2008, Ms. Kosacz and was recently listed as a “leading lawyer” for healthcare and life sciences in the 2018 Legal 500, as a “Band 1” attorney in the 2018 edition of Chambers USA: America’s Leading Lawyers for Business and recognized as a “highly recommended transactions” lawyer by IAM Patent 1000 for her “nearly three decades advising diverse companies in the industry at a deeply strategic and commercial level and overseeing their most complex and profitable deals.” Ms. Kosacz has also been listed in Northern California’s Super Lawyers from 2004 to 2013 and was selected as one of Lawdragon’s New Stars, New Worlds, and in the Lawdragon 500 Leading Lawyers in America. She received her Juris Doctor degree from the University of California, Berkeley School of Law, and her bachelor’s degree from Stanford University. Ms. Kosacz brings extensive experience in advising biotechnology companies to the Board.
As the Independent Director of XOMA Royalty, the total compensation of Barbara Kosacz at XOMA Royalty is $350,390. There are 4 executives at XOMA Royalty getting paid more, with James Neal having the highest compensation of $1,479,560.
Barbara's mailing address filed with the SEC is C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011.
Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... és Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
XOMA Royalty executives and other stock owners filed with the SEC include: